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Radionuclide Imaging in Medullary Thyroid Carcinoma: Evaluation 
of Two New Radiopharmaceuticals 
S.E.M. Clarke,* C R . Lazarus, and M.N. Maisey 
We assessed the uptake of two new radiopharmaceuticals, meta-iodo-benzylguanidine (MIBG) 
and '^'"Tc(V) dimercaptosuccinic acid (DMSA), in patients with histologically proven medullary 
thyroid carcinoma (MTC). MIBG detected tumor in 40% of patients with known primary or 
recurrent tumor. """TcfV) DMSA successfully demonstrated primary and recurrent tumor in 86% of 
patients imaged, with true negative results in 100% of patients imaged after successful surgical 
resection and a false-negative rate of 14%. We therefore suggest that '^'"Tc(V) DMSA is the imaging 
agent of choice in patients with both primary and recurrent disease. '"/ MIBG, with its high false-
negative rate, has no place in tumor localization, but its potential role in therapy warrants further 
evaluation. (Henry Ford Hosp Med J 1987:35:124-6) 
A lthough current research adds much to the genetic and biochemical knowledge of medullary thyroid carcinoma 
(MTC), the management of the patient with MTC remains a sub-
ject of debate, with present therapy limited to surgery for the 
initial tumor and local recurrence, and palliative extemal beam 
radiotherapy for distant metastases, although several chemo-
therapy trials are currently in progress. Recurrent disease is di-
agnosed biochemically by elevation of plasma calcitonin levels. 
Various imaging methods have been used to localize recurrent 
tumor, including ultrasound and computed tomography, and 
within the last few years exciting reports have appeared in the 
literature of tumor uptake by two new radiopharmaceuticals, ' ^ ' I 
meta-iodo-benzylguanidine (MIBG) and pentavalent ''""Tc di-
mercaptosuccinic acid ['»"'Tc(V) DMSA]. "'1 MIBG was devel-
oped by Wieland et al (1) as a radiopharmaceutical for imaging 
pheochromocytomas. It is a guanethidine analogue and has been 
shown by Sisson et al (2) to localize accurately 90% of pheo-
chromocytomas imaged. Since these tumors are neuroectoder-
mally derived, it was logical to assess the uptake of MIBG in 
other similarly derived tumors. In 1984, the first report appeared 
from Endo et al (3) showing uptake of " ' I MIBG in the thyroid of a 
patient with hereditary MTC. In the same year, a further case report 
by Connell et al (4) appeared, again reporting thyroidal uptake of 
'3'I MIBG in a patient with bilateral pheochromocytomas and 
MTC, Since then, several other case reports demonstrating uptake 
have been published, and the sensitivity of uptake has been 
assessed in two reported series (5,6). 
The second radiopharmaceutical which has recently appeared 
promising is '''*™Tc(V) DMSA. Unlike the trivalent preparation 
of DMSA used for renal studies, the pentavalent form has been 
shown by Ohta et al (7) to be taken up into a variety of tumors, 
including MTC. A further study (8) has shown that both primary 
and recurrent disease may be visualized and that good target-to-
background ratios facilitate the accurate localization of disease 
in both bone and soft tissue. In this study, we have evaluated ' ^ ' I 
MIBG and ''""Tc(V) DMSA uptake in patients with MTC and 
have endeavored to assess their contribution to the management 
of patients with MTC. 
Patients 
Sixteen patients were included in the study: four with heredi-
tary disease, and 12 with a sporadic form with no evidence 
of involved kindred on screening. The diagnosis of MTC was 
confirmed in all 16 patients by histological and immu-
nocytochemical techniques. All patients also had ''"^Tc meth-
ylene diphosphonate (MDP) bone scans to assess the presence 
of bone metastases, and computed tomography and con-
ventional radiography to assess extraosseous metastases, 
where appropriate. 
Five patients were studied before initial surgery, and the re-
maining patients were studied either when elevated calcitonin 
levels suggested postoperative recurrence or to assess the suc-
cess of surgical intervention. Ten patients, aged 25 to 86, were 
studied by both imaging techniques, and six other patients were 
studied with '''•^Tc(V) DMSA alone. 
Methods 
MIBG 
Before the study, all patients received blocking doses of 
Lugol's iodine to prevent uptake of free iodine by residual thy-
roid tissue. Patients were then imaged 24 and 48 hours after an 
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Fig I—'^"'Tc pertechnetate scan of patient with primary medul-
lary carcinoma involving the right lobe ofthe thyroid. Scan 
demonstrates two cold areas corresponding to sites of tumor 
(arrows). 
intravenous injection of 1 mCi (37 MBq) " ' I MIBG. Whole 
body images were acquired using a standard, large field of view 
gamma camera and high-energy collimator interfaced to a 
data processor. 
»»"'Tc(V) DMSA 
Whole body images were obtained two hours after intra-
venous injection of 2 mCi (74 MBq) '^ '"Tc(W) DMSA using 
a large field of view gamma camera and high-resolution col-
limator interfaced to a data processor. 
Fig 2 —' "/ MIBG scan of skull at 24 hours demonstrating 
uptake in left parietal bone metastasis (arrow). 
Results 
Primary diagnosis 
One patient with bilateral palpable thyroid nodules was 
imaged with '"1 MIBG, and uptake was seen in both nodules. 
Surgery subsequently confirmed the histological diagnosis of 
bilateral MTC. Three patients with primary tumors were studied 
using '''''"Tc(V) DMSA, and uptake was seen in the thyroidal 
region of two of these patients (Fig 1). The negative scan was ob-
tained in a first-degree relative of a patient with proven MTC, 
who had a normal basal calcitonin level but an abnormal 
pentagastrin stimulation test. 
R -
Recurrent disease 
'"1 MIBG successfully detected recurrent tumor, both in bone 
and soft tissue, in three patients studied (Fig 2). Five patients, 
however, had negative " ' I MIBG scans despite known metas-
tases. Another patient also had a negative " ' I MIBG scan. This 
patient was asymptomatic, had marginally elevated calcitonin 
levels, and had no tumor demonstrable by any other imag-
ing technique. '"1 MIBG imaging therefore had a sensitivity 
of 40% in the group of patients studied with primary and 
recurrent disease. 
'^"'Tc(V) DMSA successfully detected both local and distant 
metastases in ten patients studied (Figs 3 and 4). Negative scans 
were obtained in three patients, two of whom were imaged 
postoperatively after successful surgical clearance and in whom 
the postoperative calcitonin levels retumed to normal. One pa-
tient, however, had a negative '*'^ "'Tc(V) DMSA scan; this was the 
patient with an elevated postoperative calcitonin level, in whom 
Fig 3—'^'"Tc(V) DMSA scan at two hours of anterior cervical 
region of patient in Fig 1 with uptake at sites ofprimary tumor tn 
thyroid with uptake also seen in local lymph node (arrow). 
all imaging techniques, including " ' I MIBG scanning, failed 
to identify recurrent tumor '^ '"Tc( V) DMSA was therefore dem-
onstrated in this study to give a sensitivity in detection of tumor 
of 86%, with a specificity of 100%, and a false-negative rate 
of 14%. 
Discussion 
The detection of primary tumor in MTC has classically been 
undertaken using '''''"Tc pertechnetate to demonstrate the uni-
lateral cold nodules in the thyroid or the bilateral nodules in 
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# - '»'"Tc(V) DMSA has been shown in this study to be a highly 
sensitive radiopharmaceutical for the detection of primary and 
recurrent disease. The patients in whom false-negative scans 
were obtained will be followed with repeat studies, since the 
negative scans may be due to microscopic tumor deposits that 
will ultimately develop and take up sufficient ''''"'Tc(V) DMSA 
to change the status of these patients' scans from false-negative 
to tme positive. 
We have demonstrated that "™Tc(V) DMSA is the radiophar-
maceutical of choice for imaging patients with primary and 
recurrent MTC, since accurate localization of tumor recurrence 
facilitates surgical removal and also provides an objective means 
of assessing response to treatment. 
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Fig 4—^'"Tc(V) DMSA scan at two hours of anterior abdomen 
and pelvis of patient with proven multiple hepatic, rib, arul pel-
vic metastases (arrows) showing uptake in sites of known tumor. 
patients with hereditary MTC (9). Ultrasound scanning has 
complemented this radionuclide technique by confirming the 
solid nature of these nodules. 
The localization of recurrent tumor using radionuclide meth-
ods in postoperative patients whose calcitonin levels remain ele-
vated, or subsequently become elevated, has relied on '''•"Tc 
MDP bone scanning to detect bone metastases and ^ ''"iTc sulphur 
colloid to demonstrate hepatic metastases (10). Uptake of "™Tc 
MDP has also been demonstrated in extraosseous metastases 
(10,11), but many patients with known soft tissue deposits do not 
take up ''""Tc MDP. Recurrent tumor in the neck has been inves-
tigated using both ultrasound and computed tomography, but 
these techniques are unable to distinguish accurately nodes that 
are involved with recurrent tumor from those that are enlarged 
due to inflammatory change. ''^ Gallium citrate has not been suc-
cessful in demonstrating MTC (12), but -"'Thallous chloride has 
been used to image primary and recurrent thyroid carcinomas, 
including MTC (13-15). 
" ' I MIBG has been shown in this study, and in other studies 
(5,6), to have a low sensitivity in detecting MTC when compared 
with its successful use in demonstrating pheochromocytomas and 
neuroblastomas (2,16). Poor image quality and high radiation dose 
suggest that this radiopharmaceutical does not have a primary role 
in localization of tumors in patients with MTC, However, its 3-
emitting label gives it therapeutic potential, and further work is 
required to assess its place in therapy in patients whose tumors 
accumulate '^ ' I MIBG, 
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